YES. You can still complete your Inhalation General Toxicology study in 2023.
Have you considered extending your pharmaceutical product’s lifespan using inhaled medicines as a secondary indication? Know that Labcorp has increased inhalation capacity and capability in the U.S. and UK. This enables you to utilize a drug that’s been previously developed for a non-inhaled application—most commonly oral or dermal—and repurpose it to an inhaled form to capitalize on new opportunities for respiratory ailments. Explore the potential now.